Jason A Chen1, Qing Wang1, Jeremy Davis-Turak1, Yun Li1, Anna M Karydas2, Sandy C Hsu1, Renee L Sears1, Doxa Chatzopoulou1, Alden Y Huang1, Kevin J Wojta1, Eric Klein1, Jason Lee1, Duane L Beekly3, Adam Boxer2, Kelley M Faber4, Claudia M Haase5, Josh Miller6, Wayne W Poon7, Ami Rosen8, Howard Rosen2, Anna Sapozhnikova9, Jill Shapira10, Arousiak Varpetian11, Tatiana M Foroud4, Robert W Levenson9, Allan I Levey8, Walter A Kukull3, Mario F Mendez10, John Ringman12, Helena Chui11, Carl Cotman7, Charles DeCarli13, Bruce L Miller2, Daniel H Geschwind14, Giovanni Coppola14. 1. Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles. 2. Memory and Aging Center, University of California, San Francisco. 3. National Alzheimer's Coordinating Center, University of Washington, Seattle. 4. Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis. 5. Department of Psychology, School of Education and Social Policy, Northwestern University, Evanston, Illinois. 6. Department of Nutritional Sciences, Rutgers University, New Brunswick, New Jersey. 7. Institute for Memory Impairments and Neurological Disorders, University of California, Irvine. 8. Department of Neurology, Emory University, Atlanta, Georgia. 9. Department of Psychology, University of California, Berkeley. 10. Department of Neurology, University of California, Los Angeles. 11. Department of Neurology, University of Southern California, Los Angeles. 12. Department of Neurology, University of California, Los Angeles12Mary S. Easton Center for Alzheimer's Disease Research at UCLA, University of California, Los Angeles. 13. Department of Neurology, University of California, Davis. 14. Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles10Department of Neurology, University of California, Los Angeles.
Abstract
IMPORTANCE: Previous studies have indicated a heritable component of the etiology of neurodegenerative diseases such as Alzheimer disease (AD), frontotemporal dementia (FTD), and progressive supranuclear palsy (PSP). However, few have examined the contribution of low-frequency coding variants on a genome-wide level. OBJECTIVE: To identify low-frequency coding variants that affect susceptibility to AD, FTD, and PSP. DESIGN, SETTING, AND PARTICIPANTS: We used the Illumina HumanExome BeadChip array to genotype a large number of variants (most of which are low-frequency coding variants) in a cohort of patients with neurodegenerative disease (224 with AD, 168 with FTD, and 48 with PSP) and in 224 control individuals without dementia enrolled between 2005-2012 from multiple centers participating in the Genetic Investigation in Frontotemporal Dementia and Alzheimer's Disease (GIFT) Study. An additional multiancestral replication cohort of 240 patients with AD and 240 controls without dementia was used to validate suggestive findings. Variant-level association testing and gene-based testing were performed. MAIN OUTCOMES AND MEASURES: Statistical association of genetic variants with clinical diagnosis of AD, FTD, and PSP. RESULTS: Genetic variants typed by the exome array explained 44%, 53%, and 57% of the total phenotypic variance of AD, FTD, and PSP, respectively. An association with the known AD gene ABCA7 was replicated in several ancestries (discovery P=.0049, European P=.041, African American P=.043, and Asian P=.027), suggesting that exonic variants within this gene modify AD susceptibility. In addition, 2 suggestive candidate genes, DYSF (P=5.53×10(-5)) and PAXIP1 (P=2.26×10(-4)), were highlighted in patients with AD and differentially expressed in AD brain. Corroborating evidence from other exome array studies and gene expression data points toward potential involvement of these genes in the pathogenesis of AD. CONCLUSIONS AND RELEVANCE: Low-frequency coding variants with intermediate effect size may account for a significant fraction of the genetic susceptibility to AD and FTD. Furthermore, we found evidence that coding variants in the known susceptibility gene ABCA7, as well as candidate genes DYSF and PAXIP1, confer risk for AD.
IMPORTANCE: Previous studies have indicated a heritable component of the etiology of neurodegenerative diseases such as Alzheimer disease (AD), frontotemporal dementia (FTD), and progressive supranuclear palsy (PSP). However, few have examined the contribution of low-frequency coding variants on a genome-wide level. OBJECTIVE: To identify low-frequency coding variants that affect susceptibility to AD, FTD, and PSP. DESIGN, SETTING, AND PARTICIPANTS: We used the Illumina HumanExome BeadChip array to genotype a large number of variants (most of which are low-frequency coding variants) in a cohort of patients with neurodegenerative disease (224 with AD, 168 with FTD, and 48 with PSP) and in 224 control individuals without dementia enrolled between 2005-2012 from multiple centers participating in the Genetic Investigation in Frontotemporal Dementia and Alzheimer's Disease (GIFT) Study. An additional multiancestral replication cohort of 240 patients with AD and 240 controls without dementia was used to validate suggestive findings. Variant-level association testing and gene-based testing were performed. MAIN OUTCOMES AND MEASURES: Statistical association of genetic variants with clinical diagnosis of AD, FTD, and PSP. RESULTS: Genetic variants typed by the exome array explained 44%, 53%, and 57% of the total phenotypic variance of AD, FTD, and PSP, respectively. An association with the known AD gene ABCA7 was replicated in several ancestries (discovery P=.0049, European P=.041, African American P=.043, and Asian P=.027), suggesting that exonic variants within this gene modify AD susceptibility. In addition, 2 suggestive candidate genes, DYSF (P=5.53×10(-5)) and PAXIP1 (P=2.26×10(-4)), were highlighted in patients with AD and differentially expressed in AD brain. Corroborating evidence from other exome array studies and gene expression data points toward potential involvement of these genes in the pathogenesis of AD. CONCLUSIONS AND RELEVANCE: Low-frequency coding variants with intermediate effect size may account for a significant fraction of the genetic susceptibility to AD and FTD. Furthermore, we found evidence that coding variants in the known susceptibility gene ABCA7, as well as candidate genes DYSF and PAXIP1, confer risk for AD.
Authors: M A Pericak-Vance; J L Bebout; P C Gaskell; L H Yamaoka; W Y Hung; M J Alberts; A P Walker; R J Bartlett; C A Haynes; K A Welsh Journal: Am J Hum Genet Date: 1991-06 Impact factor: 11.025
Authors: Oddgeir L Holmen; He Zhang; Wei Zhou; Ellen Schmidt; Daniel H Hovelson; Arnulf Langhammer; Maja-Lisa Løchen; Santhi K Ganesh; Ellisiv B Mathiesen; Lars Vatten; Carl Platou; Tom Wilsgaard; Jin Chen; Frank Skorpen; Håvard Dalen; Michael Boehnke; Goncalo R Abecasis; Inger Njølstad; Kristian Hveem; Cristen J Willer Journal: Hum Mol Genet Date: 2014-04-12 Impact factor: 6.150
Authors: Rosa Rademakers; Marc Cruts; Kristel Sleegers; Bart Dermaut; Jessie Theuns; Yurii Aulchenko; Stefan Weckx; Tim De Pooter; Marleen Van den Broeck; Ellen Corsmit; Peter De Rijk; Jurgen Del-Favero; John van Swieten; Cornelia M van Duijn; Christine Van Broeckhoven Journal: Am J Hum Genet Date: 2005-08-30 Impact factor: 11.025
Authors: M Baker; I Litvan; H Houlden; J Adamson; D Dickson; J Perez-Tur; J Hardy; T Lynch; E Bigio; M Hutton Journal: Hum Mol Genet Date: 1999-04 Impact factor: 6.150
Authors: Dimple Bansal; Katsuya Miyake; Steven S Vogel; Séverine Groh; Chien-Chang Chen; Roger Williamson; Paul L McNeil; Kevin P Campbell Journal: Nature Date: 2003-05-08 Impact factor: 49.962
Authors: A M Pittman; A J Myers; P Abou-Sleiman; H C Fung; M Kaleem; L Marlowe; J Duckworth; D Leung; D Williams; L Kilford; N Thomas; C M Morris; D Dickson; N W Wood; J Hardy; A J Lees; R de Silva Journal: J Med Genet Date: 2005-03-25 Impact factor: 6.318
Authors: R Bashir; S Britton; T Strachan; S Keers; E Vafiadaki; M Lako; I Richard; S Marchand; N Bourg; Z Argov; M Sadeh; I Mahjneh; G Marconi; M R Passos-Bueno; E de S Moreira; M Zatz; J S Beckmann; K Bushby Journal: Nat Genet Date: 1998-09 Impact factor: 38.330
Authors: J Liu; M Aoki; I Illa; C Wu; M Fardeau; C Angelini; C Serrano; J A Urtizberea; F Hentati; M B Hamida; S Bohlega; E J Culper; A A Amato; K Bossie; J Oeltjen; K Bejaoui; D McKenna-Yasek; B A Hosler; E Schurr; K Arahata; P J de Jong; R H Brown Journal: Nat Genet Date: 1998-09 Impact factor: 38.330
Authors: Ganesh M Babulal; Yakeel T Quiroz; Benedict C Albensi; Eider Arenaza-Urquijo; Arlene J Astell; Claudio Babiloni; Alex Bahar-Fuchs; Joanne Bell; Gene L Bowman; Adam M Brickman; Gaël Chételat; Carrie Ciro; Ann D Cohen; Peggye Dilworth-Anderson; Hiroko H Dodge; Simone Dreux; Steven Edland; Anna Esbensen; Lisbeth Evered; Michael Ewers; Keith N Fargo; Juan Fortea; Hector Gonzalez; Deborah R Gustafson; Elizabeth Head; James A Hendrix; Scott M Hofer; Leigh A Johnson; Roos Jutten; Kerry Kilborn; Krista L Lanctôt; Jennifer J Manly; Ralph N Martins; Michelle M Mielke; Martha Clare Morris; Melissa E Murray; Esther S Oh; Mario A Parra; Robert A Rissman; Catherine M Roe; Octavio A Santos; Nikolaos Scarmeas; Lon S Schneider; Nicole Schupf; Sietske Sikkes; Heather M Snyder; Hamid R Sohrabi; Yaakov Stern; Andre Strydom; Yi Tang; Graciela Muniz Terrera; Charlotte Teunissen; Debora Melo van Lent; Michael Weinborn; Linda Wesselman; Donna M Wilcock; Henrik Zetterberg; Sid E O'Bryant Journal: Alzheimers Dement Date: 2018-12-13 Impact factor: 21.566
Authors: Yi Li; Annat Haber; Christoph Preuss; Cai John; Asli Uyar; Hongtian Stanley Yang; Benjamin A Logsdon; Vivek Philip; R Krishna Murthy Karuturi; Gregory W Carter Journal: Alzheimers Dement (Amst) Date: 2021-05-14
Authors: Christian Magnus Page; Sergio E Baranzini; Bjørn-Helge Mevik; Steffan Daniel Bos; Hanne F Harbo; Bettina Kulle Andreassen Journal: PLoS One Date: 2015-10-05 Impact factor: 3.240
Authors: Momoko Horikoshi; Reedik Mӓgi; Martijn van de Bunt; Ida Surakka; Antti-Pekka Sarin; Anubha Mahajan; Letizia Marullo; Gudmar Thorleifsson; Sara Hӓgg; Jouke-Jan Hottenga; Claes Ladenvall; Janina S Ried; Thomas W Winkler; Sara M Willems; Natalia Pervjakova; Tõnu Esko; Marian Beekman; Christopher P Nelson; Christina Willenborg; Steven Wiltshire; Teresa Ferreira; Juan Fernandez; Kyle J Gaulton; Valgerdur Steinthorsdottir; Anders Hamsten; Patrik K E Magnusson; Gonneke Willemsen; Yuri Milaneschi; Neil R Robertson; Christopher J Groves; Amanda J Bennett; Terho Lehtimӓki; Jorma S Viikari; Johan Rung; Valeriya Lyssenko; Markus Perola; Iris M Heid; Christian Herder; Harald Grallert; Martina Müller-Nurasyid; Michael Roden; Elina Hypponen; Aaron Isaacs; Elisabeth M van Leeuwen; Lennart C Karssen; Evelin Mihailov; Jeanine J Houwing-Duistermaat; Anton J M de Craen; Joris Deelen; Aki S Havulinna; Matthew Blades; Christian Hengstenberg; Jeanette Erdmann; Heribert Schunkert; Jaakko Kaprio; Martin D Tobin; Nilesh J Samani; Lars Lind; Veikko Salomaa; Cecilia M Lindgren; P Eline Slagboom; Andres Metspalu; Cornelia M van Duijn; Johan G Eriksson; Annette Peters; Christian Gieger; Antti Jula; Leif Groop; Olli T Raitakari; Chris Power; Brenda W J H Penninx; Eco de Geus; Johannes H Smit; Dorret I Boomsma; Nancy L Pedersen; Erik Ingelsson; Unnur Thorsteinsdottir; Kari Stefansson; Samuli Ripatti; Inga Prokopenko; Mark I McCarthy; Andrew P Morris Journal: PLoS Genet Date: 2015-07-01 Impact factor: 5.917